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The endocannabinoid 2-arachidonoylglycerol (2-AG) is involved in neuronal
differentiation. This study aimed to identify the biosynthetic enzymes responsible for
2-AG production during retinoic acid (RA)-induced neurite outgrowth of Neuro-2a cells.
First, we confirmed that RA stimulation of Neuro-2a cells increases 2-AG production
and neurite outgrowth. The diacylglycerol lipase (DAGL) inhibitor DH376 blocked 2-AG
production and reduced neuronal differentiation. Surprisingly, CRISPR/Cas9-mediated
knockdown of DAGLα and DAGLβ in Neuro-2a cells did not reduce 2-AG levels,
suggesting another enzyme capable of producing 2-AG in this cell line. Chemical
proteomics revealed DAGLβ and α,β-hydrolase domain containing protein (ABHD6) as
the only targets of DH376 in Neuro-2a cells. Biochemical, genetic and lipidomic studies
demonstrated that ABHD6 possesses DAGL activity in conjunction with its previously
reported monoacylglycerol lipase activity. RA treatment of Neuro-2a cells increased
by three-fold the amount of active ABHD6. Our study shows that ABHD6 exhibits
significant DAG lipase activity in Neuro-2a cells in addition to its known MAG lipase
activity and suggest it is involved in neuronal differentiation.
Keywords: α,β-hydrolase domain containing protein 6, diacylglycerol lipase, 2-AG, endocannabinoids, lipidomics,
chemical proteomics, activity-based protein profiling
INTRODUCTION
The endocannabinoid 2-archidonoylglycerol (2-AG) is an important signaling lipid in the central
nervous system (CNS). It acts as a retrograde messenger that activates the presynaptic cannabinoid
receptor type 1 (CB1R), thereby regulating neurotransmitter release. 2-AG is involved in a variety
of physiological processes, including modulation of memory, energy balance, and emotional states,
such as stress and anxiety (Di Marzo, 2011). Biochemical, pharmacological and genetic studies
have established diacylglycerol lipases α and β (DAGLα, DAGLβ) as the main biosynthetic enzymes
that produce 2-AG in the brain by catalyzing the sn-1-specific hydrolysis of diacylglycerol (DAG)
to generate 2-AG (Bisogno et al., 2003; Figure 1). For example, congenital deletion of DAGLα or
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FIGURE 1 | Schematic overview of 2-AG signaling and metabolism. CB1R, Cannabinoid receptor type 1; DAGL, diacylglycerol lipase; MAGL, monoacylglycerol
lipase; ABHD, α,β-hydrolase domain containing protein; DAG, diacylglycerol; 2-AG, 2-arachidonoylglycerol; AA, arachidonic acid.
DAGLβ resulted in 80 and 50% reduction, respectively, of brain
2-AG levels in knockout (KO) mice as compared to wild type
(WT) littermates (Gao et al., 2010). Pharmacological studies with
covalent, irreversible, dual DAGL inhibitors, such as DH376 and
DO34, showed that acute blockade of 2-AG biosynthesis in the
mouse brain reduced neuroinflammatory responses (Ogasawara
et al., 2016), reversed LPS-induced anapyrexia (Ogasawara et al.,
2016), reduced food intake (Deng et al., 2017), and modulated
cocaine-seeking behavior (McReynolds et al., 2018) and stress
responses (Bluett et al., 2017).
The life span of 2-AG signaling at the synapse is tightly
controlled. Monoacylglycerol lipase (MAGL) (Dinh et al., 2002)
and α,β-hydrolase domain containing protein 6 and 12 (ABHD6,
ABHD12) have been identified as the key enzymes terminating
the physiological role of 2-AG. They hydrolyze the ester bond
in 2-AG, thereby generating glycerol and arachidonic acid (AA)
(Blankman et al., 2007; Marrs et al., 2010; Figure 1). MAGL is
the predominant lipase in the brain covering over 85% of 2-AG
hydrolysis, whereas ABHD6 and ABHD12 account for 4 and 9%,
respectively (Blankman et al., 2007).
2-Archidonoylglycerol signaling is not only important in the
adult brain, multiple studies have also provided evidence of a
functional role of 2-AG during neural developmental processes
(Oudin et al., 2011b), including axonal growth and guidance
(Bisogno et al., 2003; Harkany et al., 2007; Watson et al.,
2008; Wu et al., 2010), differentiation (Jung et al., 2011), and
neurogenesis (Gao et al., 2010; Oudin et al., 2011a). In adult mice,
DAGLα is mainly restricted to postsynaptic sites on neurons,
whereas DAGLβ is expressed in microglial cells. Importantly,
DAGLα and DAGLβ are expressed by neurons at developing
axonal tracts during neuronal development (Bisogno et al., 2003;
Berghuis et al., 2007; Watson et al., 2008; Oudin et al., 2011a).
Jung et al. (2011) have investigated the role of DAGLs in
neuronal differentiation using retinoic acid (RA)-induced neurite
outgrowth in murine neuroblastoma cell line Neuro-2a and
found that RA elevated cellular 2-AG levels in Neuro-2a cells
during differentiation and recombinant expression of DAGLα
or DAGLβ increased neurite outgrowth, whereas silencing the
expression of DAGLs using shRNAs reduced the number of cells
with neurites. The contribution of the endogenously expressed
DAGL enzymes to 2-AG biosynthesis in these cells is, however,
less clear. Here, we sought to further test the role of the
two DAGL isoforms in 2-AG biosynthesis in Neuro-2a using
pharmacological, analytical, and genetic methods.
MATERIALS AND METHODS
Materials, Probes, and Inhibitors
Fluorophosphonate-rhodamine (FP-TAMRA) was purchased
from Thermo Fisher, as well as synthesized in-house as previously
described (Janssen et al., 2018). FP-Biotin was purchased from
Santa Cruz Biotechnology, KT182 was purchased from Sigma
Aldrich. Fluorophosphonate-BODIPY (FP-BODIPY) (Janssen
et al., 2018), MB064 (Baggelaar et al., 2013), MB108 (Baggelaar
et al., 2013), DH376 (Ogasawara et al., 2016), and LEI105
(Baggelaar et al., 2013) were synthesized as previously described.
All synthesized compounds were at least 95% pure as analyzed
by LC-MS, NMR, and HRMS. Primers were ordered from
Sigma Aldrich or Integrated DNA Technologies. Other
chemicals, reagents were purchased from Sigma Aldrich, unless
indicated otherwise.
Cloning General
Full-length human DAGLα and ABHD6 cDNA (Source
Bioscience) was cloned into the mammalian expression vector
pcDNA3.1, containing ampicillin and neomycin resistance
genes. The inserts were cloned in frame with a C-terminal
FLAG-tag and site-directed mutagenesis was used to generate
the catalytically inactive DAGLαS472A and ABHD6S148A
mutants. pcDNA3.1 containing the gene for eGFP was used as a
transfection control. Plasmids were isolated from transformed
XL-10 Z-competent cells (Midi/Maxi Prep, Qiagen), sequenced
and verified (CLC Main Workbench).
Cell Culture
General
Neuro-2a (murine neuroblastoma) and HEK293-T (human
embryonic kidney) cells were cultured at 37◦C and 7% CO2 in
DMEM containing phenol red, stable glutamine, newborn bovine
serum (10% v/v; Thermo Fisher), and penicillin and streptomycin
(200 µg/mL each; Duchefa). Medium was replaced every 2–3 days
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and cells were passaged twice a week at ∼90% confluence by
resuspension in fresh medium. Cell lines were from ATCC and
were regularly tested for mycoplasma contamination. Cultures
were discarded after 2–3 months of use.
Single Cell Clone Generation
Single cell clones of Neuro-2a cells were generated by seeding
cells at a density of 0.5, 1, 2, or 4 cells per well in 96-wells plates.
After several days, wells plates were screened for growth of single
cell clones by phase-contrast microscopy (EVOS Auto FL2).
Single cell clones were selected and expanded to full cultures.
Transient Transfections (HEK293-T)
One day prior to transfection, HEK293-T cells were seeded at
1 × 106 cells/well in 6-wells plates or at 0.3 × 106 cells/well
in 12-wells plates. Prior to transfection, culture medium was
aspirated and a minimal amount of complete medium was added.
A 3:1 (m/m) mixture of polyethyleneimine (PEI) and plasmid
DNA (1.25 µg in 6-well, 0.625 µg in 12-well) was prepared
in serum-free culture medium and incubated for 15 min at
rt. Transfection was performed by dropwise addition of the
PEI/DNA mixture to the cells. Transfection with pcDNA3.1
encoding GFP was used to generate control samples. Twenty-four
hours post-transfection, culture medium was replaced. In situ
treatments were initiated 48 h post-transfection. Transfection
efficiency was checked by fluorescence microscopy on eGFP
transfected samples (EVOS FL2 Auto, GFP-channel).
In situ Treatments
The term in situ is used to designate experiments in which
live cell cultures are treated. Neuro-2a cells were seeded at
0.3× 106 cells/well in 12-wells plates, 2.5× 106 cells/dish in 6 cm
dishes, 48 h prior to treatment. HEK293-T cells from transient
transfections were used at 24–48 h. post-transfection. Culture
medium was aspirated and after a careful PBS wash, treatment
medium (serum-free DMEM) containing vehicle (0.1% DMSO)
or DH376 (100 nM – 1 µM as indicated in figure legends)
was added. After incubation for 2 h at 37◦C and 7% CO2,
treatment medium was aspirated, and cells were rinsed with PBS.
Subsequently cells were harvested by resuspension in PBS and
pelleted (1000 g, 3 min, rt). Cell pellets were flash frozen in liquid
nitrogen and stored at−80◦C until further use.
Retinoic Acid Stimulation
Neuro-2a cells were seeded at 1× 105 cells/well in 6-well plates or
1× 106 cells/dish in 10 cm dishes. One day after seeding, medium
was aspirated and RA stimulation was initiated by adding DMEM
containing 2% newborn bovine serum and all-trans-retinoic acid
(50 µM) or vehicle (0.1% DMSO). For Figure 2D, co-treatment
was done with vehicle (0.1% DMSO) or DH376 (100 nM)
throughout the entire differentiation process. Neurite outgrowth
was investigated after 24, 48 or 72 h using phase contrast
microscopy (Olympus or EVOS FL2 Auto, phase contrast, large
ring). Neurite outgrowth was quantified by counting the cells
with a minimum of two outgrowth processes longer than the cell
body, as a percentage of the total number of cells (three dishes,
five images per dish). Cell count and viability were checked by
TABLE 1 | sgRNA targets, sgRNA oligos (top, bottom) and T7E1 primers
(forward, reverse).
sgRNA target # Primer sequences




























Constructs indicated with an asterisk (∗) were used to generate double and
triple knockdowns.
Trypan blue staining and automated cell counting (TC20TM Cell
Counter, Bio-Rad).
CRISPR/Cas9-Mediated Knockdowns
Guide Design and Constructs
Two sgRNA’s, in early exons, with high efficiency and specificity
as predicted by CHOPCHOP v2 online web tool1 (Labun et al.,
2016) were selected. Guides were cloned into the BbsI restriction
site of plasmid px330-U6-Chimeric_BB-CBh-hSpCas9 (gift from
Feng Zhang, Addgene plasmid #42230) as previously described
(Cong et al., 2013; Ran et al., 2013). Constructs and primers are
annotated in Table 1.
Knockdown Population Generation
Neuro-2a cells were transfected three times (once every 3 days)
to yield populations with a high knockdown efficiency. Cells
were seeded at days 0, 3, and 6 and transfected at days 1, 4,
and 7. Samples for T7E1 assays, and for ABPP were harvested
at days 2, 5, and 11 and after additional several weeks of cell
culture. One day prior to the first transfection, Neuro-2a cells
were seeded to a 6-well plate to reach 80% confluence at the
time of transfection. Prior to transfection, culture medium was
aspirated and 2 mL of fresh medium was added. A 5:1 (m/m)
mixture of PEI (17.5 µg per well) and plasmid DNA (total 3.5 µg
1http://chopchop.cbu.uib.no
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per well) was prepared in serum-free culture medium (250 µL
each) and incubated (15 min, rt). Transfection was performed by
dropwise addition of the PEI/DNA mixture to the cells. Twenty-
four hours post-transfection, the culture medium was replaced,
a small number of cells was harvested for analysis by T7E1
assay and ABPP, while the remainder of the cells was kept in
culture under standard conditions for following transfections.
After three transfection rounds, the cells were cultured according
to standard protocol. Aliquots of knockdown cell populations
were prepared in complete DMEM +10% DMSO and stored at
−150◦C. Efficiency of knockdown was verified over time. Cells
were discarded after 3 months of culture.
T7E1 Assay
Genomic DNA was obtained by mixing 50 µL QuickExtractTM
(Epicentre) with cell pellet (∼10% of a well from a 6-well plate).
The samples were incubated at 65◦C for 6 min, mixed and
incubated at 98◦C for 2 min. Genomic DNA extracts were diluted
in sterile water and directly used in PCR reactions. Genomic
PCR reactions were performed on 2.5–5 µL isolated genomic
DNA extract using Phusion High-Fidelity DNA Polymerase
(Thermo Fisher) in Phusion HF buffer Green (Thermo Fisher)
in a final volume of 20 µL, for primers see Table 1.
For the T7E1 assay, genomic PCR products were denatured
and reannealed in a thermocycler using the following program:
5 min at 95◦C, 95 to 85◦C using a ramp rate of −2◦C/s,
85 to 25◦C using a ramp rate of −0.2◦C/s. Annealed PCR
product (8.5 µL) was mixed with NEB2 buffer (1 µL) and T7
endonuclease I (5 U, 0.5 µL; New England Biolabs), followed
by a 30 min incubation at 37◦C. Digested PCR products
were analyzed using agarose gel electrophoresis with ethidium
bromide staining. A sample without T7 endonuclease I was also
analyzed as control. Agarose gels were analyzed using Image
LabTM Software (Bio-Rad) and DNA modification efficiency was
expressed as percentage T7E cleavage (volume integral of digested
bands/volume integral all bands× 100%). Uncropped images can
be found in Supplementary Figure S6.
Cell Lysate Preparation
Cells were harvested in PBS and pelleted by centrifugation
(1000 × g, 3–5 min, rt). Cell pellets were snap-frozen and stored
at −80◦C until further use. Cell pellets were thawed on ice,
resuspended in cold lysis buffer (20 mM HEPES pH 7.2, 2 mM
DTT, 250 mM sucrose, 1 mM MgCl2, 2.5 U/mL benzonase)
and incubated on ice (15–30 min). Protein concentrations were
determined by a Quick StartTM Bradford Protein Assay (Bio-
Rad). After dilution to 2 mg/mL in sucrose lysis buffer or storage
buffer (20 mM HEPES pH 7.2, 2 mM DTT), samples were used or
flash frozen in liquid nitrogen and stored at −80◦C until further
use. DTT was left out of all buffers for samples intended for
click-chemistry.
Tissue Lysate Preparation
Mice were housed in a pathogenic-free facility in accordance
with the National Institutes of Health; the Institutional Animal
Care and Use Committee at the University of Washington
approved all experiments. Flash frozen whole brain tissues
(excluding cerebellum) were obtained from wild-type (male,
10 weeks) and Abhd6−/− mice (male, 18 weeks). Abhd6−/− mice
were generated in by a targeting construct designed to delete
exon 5 of the Abhd6 gene, which includes the predicted catalytic
serine S148 contained within a canonical GXSXG motif, and
led to absence in ABHD6 expression and activity (Deng et al.,
manuscript submitted). Frozen tissues were thawed on ice and
dounce-homogenized in cold lysis buffer (20 mM HEPES pH
7.2, 2 mM DTT, 250 mM sucrose, 1 mM MgCl2, 2.5 U/mL
benzonase). After incubation on ice for 15 min, tissue debris was
pelleted by two sequential centrifugation steps (2500 × g, 3 min,
4◦C). Soluble lysates were diluted to 2 mg/mL in storage buffer
(20 mM HEPES pH 7.2, 2 mM DTT), flash-frozen in aliquots and
stored at−80◦C until further use.
Activity-Based Protein Profiling
Gel-Based ABPP: Single Probe
Whole lysate (2 mg/mL) was incubated with activity-based
probes MB064 (250 nM – 2 µM, 20 min, rt) or FP-TAMRA
(500 nM, 20 min, rt). The reaction was quenched with Laemmli
buffer (30 min, rt) and 20 µg protein was resolved by
SDS-PAGE (10% acrylamide gel) along with protein marker
(PageRulerTM Plus, Thermo Fisher). In-gel fluorescence was
detected in the Cy3- and Cy5-channel on a ChemiDocTM MP
imaging system (Bio-Rad) and gels were stained with coomassie
after scanning. Fluorescence was quantified and normalized
to coomassie staining using ImageLabTM software (Bio-Rad)
and data was processed in Excel (Microsoft) and GraphPad
Prism 7 (GraphPad). Uncropped images can be found in
Supplementary Figure S6.
Gel-Based ABPP: Probe Mixture
Whole lysates (DTT-free, 2 mg/mL) were incubated with
activity-based probe MB064 (2 µM, 10 min, rt), followed
by incubation with FP-TAMRA (500 nM, 10 min, rt) and a
subsequent conjugation to Cy5-azide by incubation with click-
mix (2.5/10 µM Cy5-N3, 67 mM sodium ascorbate, 4 mM
CuSO4(H2O)5, 1.3 mM THPTA; 30 min, rt). The reaction was
quenched with Laemmli buffer (30 min, rt) and 15 µg protein was
resolved by SDS-PAGE (10% acrylamide gel) along with protein
marker (PageRulerTM Plus, Thermo Fisher). In-gel fluorescence
was detected in the Cy3- and Cy5-channel on a ChemiDocTM MP
imaging system (Bio-Rad) and gels were stained with coomassie
after scanning. Fluorescence was quantified and normalized
to coomassie staining using ImageLabTM software (Bio-Rad)
and data was processed in Excel (Microsoft) and GraphPad
Prism 7 (GraphPad). Uncropped images can be found in
Supplementary Figure S6.
Chemical Proteomics With Label-Free Quantification
The chemical proteomics workflow was modified from a
previously published protocol (van Rooden et al., 2018). In short,
for general profiling of the serine hydrolases the whole lysates
(250 µg protein, n = 4) were incubated with serine hydrolase
probe cocktail (10 µM MB108, 10 µM FP-Biotin, 30 min, 37◦C,
300 rpm). Denatured protein samples (1% SDS, 5 min, 100◦C)
were also analyzed as a negative control. For DH376 target
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identification, the whole lysates of DH376 treated cells (250 µg
protein, n = 4) were conjugated to biotin-azide by the addition
of 10× concentrated click mix (final: 1 mM CuSO4(H2O)5,
0.56 mM sodium ascorbate, 0.2 mM THPTA, 0.04 mM biotin-
azide in MilliQ) and subsequent incubation (60 min, 37◦C,
300 rpm). A vehicle treated sample was also analyzed as a negative
control. Precipitation, alkylation, avidin enrichment, on-bead
digestion and sample preparation was performed as described
(van Rooden et al., 2018). Dried peptides were stored at −20◦C
until LC-MS analysis. Prior to measurement, samples were
reconstituted in 50 µL LC-MS solution and transferred to LC-MS
vials. Analysis was performed using Progenesis QIP (Waters)
as published, using the following cut-offs: ≥2-fold enrichment
compared to negative control, ≥2 peptides, ≥1 unique peptide,
peptide ion correlations ≥0.7. Peptide lists are provided in
Supplementary Table S1.
Lipidomics
Sample Preparation: Neuro-2a Retinoic Acid
Stimulation
Neuro-2a cells were seeded at 0.75 × 106 cells/10 cm dish). One
day after seeding, medium was aspirated and RA stimulation
was initiated by adding DMEM containing 2% serum and RA
(50 µM) or vehicle (0.1% DMSO). After 48–72 h (as indicated
in figure legends) neurite outgrowth was assessed using phase
contrast microscopy (Olympus). Cells were washed with PBS and
harvested by resuspension in PBS (for RA stimulated cells, five
dishes were combined to yield enough cells). Cells were pelleted
(200 g, 10 min, rt) and resuspended in 1 mL PBS. Cell count and
viability were checked by Trypan blue staining and automated cell
counting (TC20TM Cell Counter, Bio-Rad) and 1 or 2× 106 cells
were pelleted (1000 g, 3 min, rt). Pellets were flash frozen in liquid
nitrogen and stored at−80◦C until lipid extraction.
Sample Preparation: Neuro-2a Single Cell Clones
Neuro-2a cells were seeded at 1.25 × 106 cells/dish in a 10 cm
dish. One day after seeding, medium was aspirated and cells were
cultured in 2% serum and vehicle (0.1% DMSO). After 48 h,
cells were washed with PBS and harvested by resuspension in
PBS. Cells were pelleted (200 g, 5 min, rt) and resuspended in
PBS. Cell count and viability were measured by Trypan blue
staining and automated cell counting (TC20TM Cell Counter,
Bio-Rad) and 1× 106 cells were pelleted (1000 g, 3 min, rt). Pellets
were flash frozen in liquid nitrogen and stored at −80◦C until
lipid extraction.
Sample Preparation: Neuro-2a Knockdown
Populations
Neuro-2a cells were seeded at 2.5 × 106 cells/dish in a 6 cm
dish 48 h prior to treatment. Alternatively, HEK293-T cells
from transient transfections were used at 48 h post-transfection
(6-wells format). Culture medium was aspirated and after a
PBS wash, treatment medium (serum-free DMEM) containing
vehicle (0.1% DMSO) or DH376 (100 nM) was added. After
incubation for 2 h at 37◦C and 7% CO2, treatment medium
was aspirated, and cells were washed with PBS. Subsequently
cells were harvested by resuspension in 1250 µL PBS. Cell
count and viability were measured by Trypan blue staining and
automated cell counting (TC20TM Cell Counter, Bio-Rad). Cells
from 1000 µL suspension were spun down (1000 × g, 3 min, rt)
in a low binding Eppendorf tube. Pellets were flash frozen
in liquid nitrogen and stored at −80◦C until lipid extraction.
The remaining cell suspension (∼200 µL) was flash frozen and
used to determine the protein concentration of each sample.
The suspension was thawed on ice and cells were lysed by
sonication using a probe sonicator (Heidolph; 5 s per sample,
10% amplitude). Protein concentrations (∼1 mg/mL) were
determined by a Quick StartTM Bradford Protein Assay (Bio-Rad)
and were used for normalization of the lipid abundance.
Lipid Extraction
Lipid extraction was performed as previously described (Van
Esbroeck et al., 2017) with minor adaptations. In brief, cell
pellets were transferred into 1.5 mL Eppendorf tubes, spiked with
10 µL of deuterated internal standard mix (Table 2), followed by
addition of 0.5% NaCl and later 100 µL of ammonium acetate
buffer (0.1 M, pH 4) was added. After addition of 1000 µL methyl
tert-butyl ether (MTBE), the tubes were thoroughly mixed for
5 min using a bullet blender (Next Advance) at medium speed,
followed by a centrifugation step (16,000 × g, 5 min, 4◦C). Then
850 µL of the upper MTBE layer was transferred to clean 1.5 mL
Eppendorf tubes. Samples were dried in a SpeedVac (Eppendorf)
followed by reconstitution in 50 µL of acetonitrile:water (90:10,
v/v). The reconstituted samples were centrifuged (16,000 × g,
3 min, 4◦C) before transferring into LC-MS vials. 5 µL of each
sample was injected into the LC-MS/MS system.
LC-MS/MS Analysis
LC-MS/MS analysis was performed as previously described
(Kantae et al., 2017; Van Esbroeck et al., 2017) with minor
adaptations. A targeted analysis of 31 compounds, including
endocannabinoids and related N-acylethanolamines (NAEs) and
free fatty acids (Table 2), was detected using an Acquity UPLC I
class Binary solvent manager pump (Waters) in conjugation with
AB SCIEX 6500 quadrupole-ion trap (AB Sciex). The separation
was performed with an Acquity HSS T3 column (2.1 × 100 mm,
1.8 µm) maintained at 45◦C. The aqueous mobile phase A
consisted of 2 mM ammonium formate and 10 mM formic
acid, and the organic mobile phase B was acetonitrile. The flow
rate was set to 0.55 mL/min; initial gradient conditions were
55% B held for 2 min and linearly ramped to 100% B over
6 min and held for 2 min; after 10 s the system returned
to initial conditions and held 2 min before next injection.
Electrospray ionization-MS and a selective Multiple Reaction
Mode (sMRM) was used for endocannabinoid quantification.
Individually optimized MRM transitions using their synthetic
standards for target compounds and internal standards are
described in Table 2.
DAG Analysis
LC-MS/MS analysis of DAG (16:0, 20:4) was performed as
described in the above section with the following adaptations.
The mobile phase A was 10 mM ammonium formate and 10 mM
formic acid in 60:40 (v/v%) acetonitrile:water, the mobile phase
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TABLE 2 | LC-MS standards and internal standards for lipidomics analysis.
Standards
Abbreviation Metabolite Q1 Q3 Polarity
DAG (16:0, 20:4) 1-Palmitoyl-2-arachidonoyl-sn-glycerol 634 313 +
1&2-AG 2&1-Arachidonoylglycerol (20:4) 379 287 +
AEA Anandamide (20:4) 348 62 +
DHEA N-Docosahexaenoylethanolamide (22:6) 372 62 +
LEA N-Linoleoylethanolamide (18:2) 324 62 +
NADA N-Arachidonoyl dopamine (28:4) 440 137 +
OEA N-Oleoylethanolamide (18:1) 326 62 +
PEA N-Palmitoylethanolamide (16:0) 300 62 +
SEA N-Stearoylethanolamide (18:0) 328 62 +
2-AGE 2-Arachidonyl glycerol ether (20:4) 365 273 +
DEA N-Docosatetraenoylethanolamide (22:4) 376 62 +
DGLEA Dihomo-γ-Linolenoyl Ethanolamide (18:3) 350 62 +
O-AEA O-Arachidonoyl ethanolamine (20:4) 348 62 +
2-LG 2-Linoleoyl glycerol (18:2) 355 263 +
1-LG 1-Linoleoyl glycerol (18:2) 355 263 +
2-OG 2-Oleoyl glycerol (18:1) 357 265 +
EPEA Eicosapentaenoyl ethanolamide (20:5) 346 62 +
POEA N-Palmitoleoylethanolamide (16:1) 298 62 +
ETAEA Eicosatrienoic acid ethanolamide (20:3) 350 62 +
PDEA N-Pentadecanoyl ethanolamide (15:0) 286 62 +
α-LEA N-α-Linolenylethanolamide (18:2) 322 62 +
OA Oleic acid (18:1) 281 263 –
LA Linoleic acid (18:2-ω6) 279 261 –
α-LA α-Linolenic acid (18:3-ω3) 277 233 –
γ-LA γ-Linolenic acid (18:3-ω6) 277 233 –
DGLA Dihomo-γ-linolenic acid (20:3-ω6) 305 261 –
MA Mead acid (20:3-ω9) 305 261 –
AA Arachidonic Acid (20:4-ω6) 303 259 –
EPA Eicosapentaenoic acid (20:5-ω3) 301 257 –
DTA Docosatetraenoic acid (22:4-ω6) 332 288 –
DHA Docosahexaenoic acid (22:6-ω3) 327 283 –
Internal standards
DAG (34:0) 1-margaroyl-2-margaroyl-sn-glycerol 614 327 +
2-AG (20:4)-d8 2-Arachidonoylglycerol-d8 387 294 +
PEA (16:0)-d4 Palmitoyl ethanolamide-d4 304 62 +
SEA (18:0)-d3 Stearoyl ethanolamide-d3 331 62 +
OEA (18:1)-d4 Oleoyl ethanolamide-d4 330 66 +
LEA (18:2)-d4 Linoleoyl ethanolamide-d4 328 66 +
AEA (20:4)-d8 Arachidonoyl ethanolamide-d8 356 62 +
DHEA (22:6)-d4 Docosahexaenoyl ethanolamide-d4 376 66 +
NADA (28:4)-d8 N-Arachidonoyl dopamine-d8 448 137 +
B was 10 mM ammonium formate and 10 mM formic acid in
10:90 (v/v%) acetonitrile:isopropanol. The flow rate was set to
0.4 mL/min; initial gradient conditions were 50% B for 0.5 min
and linearly ramped to 60% B at 2 min, then ramped to 90% B at
6 min; after 6 s the system returned to initial conditions and held
1.4 min before next injection.
NBD-HPTLC Assay
Whole lysates of HEK293-T transiently expressing eGFP
(control), DAGLα, ABHD6 or their catalytically inactive serine
mutants were prepared as described above. Lysate (100 µg
protein) was mixed with 5 µM DAG-NBD (Cayman Chemical;
2 mM stock in EtOH) in HEPES buffer (20 mM HEPES pH7.2,
2 mM DTT) and incubated (30 min, 37◦C, 600 rpm, dark). As
a control, a sample without protein was also analyzed. After
incubation, lipids were extracted by a Bligh and Dyer extraction.
In short, 800 µL chloroform:methanol (1:1, v/v) and 110 µL
MilliQ were added to the sample. Phases were separated by
centrifugation (5 min, 13,000 × g) and the bottom layer was
transferred to a dark Eppendorf tube. The upper layer was
extracted once more by adding 400 µL chloroform. The lipid
extract was dried in a SpeedVac (Eppendorf) (45 min, 45◦C).
Lipids were reconstituted in 40 µL methanol, and lipids (2 µL,
n = 3) were separated by thin layer chromatography on high
performance thin layer chromatography (HPTLC) Silica gel 60
plates (Merck) using chloroform:methanol (80:20, v/v) as eluent.
NBD-labeled lipids were detected using a Typhoon Imaging
system (GE Healthcare Bio-Science) (Alexa488 channel, 250V).
Fluorescence was quantified using ImageLabTM software (Bio-
Rad). Excel (Microsoft) and GraphPad Prism 7 (GraphPad)
were used for further analysis. DAG-NBD was expressed as
fraction of the total NBD intensity in each lane and normalized
to eGFP samples.
NBD-HPTLC assays on tissue lysates were performed as
described above with the following modifications. Tissue lysate
was pre-incubated with vehicle (DMSO) or inhibitor (100 nM,
30 min, 37◦C). DAG-NBD was used at with 10 µM and incubated
for 15 min (37◦C, 600 rpm, dark).
Western Blot
Cell lysates were denatured with Laemmli buffer (30 min, rt)
and 20 µg lysate was resolved on a 10% acrylamide SDS-PAGE
gel along with PageRulerTM Plus Protein Marker (Thermo
Scientific). Proteins were transferred to 0.2 µm polyvinylidene
difluoride membranes by Trans-Blot TurboTM Transfer system
(Bio-Rad). Membranes were washed with TBS (50 mM Tris,
150 mM NaCl) and blocked with 5% milk in TBS-T (50 mM
Tris, 150 mM NaCl, 0.05% Tween 20) (1 h, rt). Membranes were
then incubated with primary antibody mouse-anti-FLAG (F3156,
Sigma Aldrich; 1:2500 in 5% milk in TBS-T, 45 min, rt) washed
with TBS-T, incubated with secondary donkey-anti-mouse-
Alexa647 (A-31571, Thermo Fisher; 1:10000 in 5% milk TBS-T,
45 min, rt), and washed with TBS-T and TBS. Fluorescence
was detected on the ChemiDocTM MP imaging system (Bio-
Rad) in the Alexa647 channel, and Cy3/Cy5 channels for the
protein marker. Signal was normalized to coomassie staining
using ImageLabTM software (Bio-Rad) and data was processed in
Excel (Microsoft) and GraphPad Prism 7 (GraphPad).
Statistical Methods
All statistical analyses and methods are included in the respective
figure or table captions. In brief: all data are shown as
the mean ± SEM, unless indicated otherwise. A Student’s
t-test (two-tailed, unpaired) was used to determine statistical
significance, with a Holm–Sidak multi-comparison correction for
proteomics data using GraphPad Prism 7 (GraphPad). Samples
were compared to WT/Vehicle/GFP controls and statistical
significance is indicated as ∗p< 0.05, ∗∗p< 0.01, ∗∗∗p< 0.001.
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RESULTS
To investigate the role of DAGL in neuronal differentiation,
Neuro-2a cells were incubated with RA, which induced a
time-dependent outgrowth of neurites (Figures 2A,B). This
resulted in increased 2-AG net levels as determined by liquid
chromatography-mass spectrometry (LC-MS) (Figure 2C).
These findings confirm and extend a previous study (Jung
et al., 2011). Of note, anandamide (AEA) and AA levels were
also significantly increased (Figure 2C). To check whether
endogenously expressed DAGLs are responsible for the 2-AG
production during differentiation, the cells were incubated
with the dual DAGL inhibitor DH376. 2-AG and AA, but not
AEA, levels were reduced by DH376 (Figure 2D). The inhibitor
also impaired differentiation of Neuro-2a cells, as indicated
by the reduced fraction of neurite bearing cells after 24, 48,
and 72 h of RA stimulation (Figure 2B). This suggested that
DAGL-dependent 2-AG and/or AA production plays a role in the
differentiation process, as previously suggested (Jung et al., 2011).
To investigate which DAGL isoform is responsible for 2-AG
production in Neuro-2a cells, we used a genetic approach as
no subtype-specific DAGL inhibitors are currently available. Of
note, single cell heterogeneity (in 2-AG production and neurite
outgrowth) prevented the unequivocal analysis of single cell clone
knockouts (Supplementary Figure S1). Therefore, disruption of
DAGLα and DAGLβ genes was performed by three sequential
rounds of transfection of Cas9 and single guide RNA’s (sgRNA)
in Neuro-2a cell populations (Supplementary Figures S2A–C).
This yielded three Neuro-2a knockdown (KD) populations:
DAGLα KD, DAGLβ KD, and DAGLα-β KD. DAGLα and
DAGLβ activity in these cell populations was measured using
activity-based protein profiling (ABPP) to determine the
efficiency of the genetic disruption. ABPP is a chemical proteomic
method that uses chemical probes (e.g., fluorophosphonates (FP)
or β-lactones) to assess the functional state of various enzymes,
here DAGLα and DAGLβ, in native biological systems. When
coupled to fluorescent reporter groups, activity-based probes
(ABPs) enable visualization and quantification of enzymatic
activity in complex proteomes by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) and in-gel
fluorescence scanning. When coupled to a biotin reporter group,
ABPs enable affinity enrichment and identification of enzyme
activities by mass spectrometry (MS)-based proteomics. Gel-
based ABPP with a fluorescent FP-probe (FP-TAMRA) and
β-lactone probe MB064 showed a reduction (>70%) of active
DAGLβ in the DAGLβ KD and DAGLα-β KD populations
(Figures 3A,B), without affecting other serine hydrolase
activities. LC-MS-based chemical proteomics confirmed these
findings (Figure 3D). Of note, no DAGLα activity was
observed in either of the populations, including WT Neuro-2a
(Figures 3A,B). The residual DAGLβ activity can be explained
by a transfection efficiency below 100% and by insertion or
deletion of a full codon upon Cas9-mediated DNA modification,
thus preventing the frameshift that generally results in an
early stop-codon.
Next, the 2-AG levels of the genetically modified Neuro-2a
populations were quantified using LC-MS. Surprisingly, despite
a >70% reduction in levels of active DAGLβ and no detectable
DAGLα activity, the 2-AG levels in the DAGLα KD, DAGLβ KD
or double DAGLα-β KD populations were not different from WT
populations (Figure 3C). To test whether the 2-AG production
in the KD populations was still sensitive to DH376 treatment,
cells were incubated in situ (live cells) with DH376 (100 nM,
2 h). Lipidomics analysis on these samples revealed that DH376
again reduced cellular levels of both 2-AG and AA by 50% in
all populations (Figure 3C). Of note, a small but significant
increase in AEA levels was detected in the double DAGLα-β
KD populations (Figure 3C), which could be due to increased
levels of active ABHD4 (Figure 3D). Taken together, these data
suggest that residual DAGLβ activity may be responsible for
generating the entire pool of 2-AG, which seems unlikely, or that
an alternative, unidentified enzyme, which is sensitive to DH376,
contributes to 2-AG production in Neuro-2a cells.
To identify all 2-AG producing enzymes targeted by DH376
in Neuro-2a, we leveraged a chemical proteomics strategy in
which the alkyne moiety of DH376 served as a ligation handle
FIGURE 2 | RA-induced differentiation increased cellular 2-AG levels and is reduced by DH376 treatment. (A–C) Neuro-2a cells were differentiated with RA (50 µM,
2% serum, 24–72 h) in the presence or absence of inhibitor DH376 (100 nM). (A) Phase contrast microscopy of representative differentiated and non-differentiated
Neuro-2a cultures (72 h incubation). Scale bar: 50 µm. (B) Neuro-2a differentiation was quantified as the percentage of neurite bearing cells [mean ± SEM (n = 3),
t-test: ∗∗∗p < 0.001 vehicle versus RA, #p < 0.05, ##p < 0.01 RA versus RA-DH376]. (C) Lipidomics analysis on vehicle and RA-stimulated cells (72 h). Lipid
abundance was normalized to the number of cells. Data is expressed as % of vehicle [mean ± SEM (n = 5), t-test: ∗∗∗p < 0.001]. (D) Lipidomics analysis on in situ
DH376-treated Neuro-2a (100 nM, 2 h). Lipid abundance was normalized for the amount of protein. Data is expressed as % of vehicle [mean ± SEM (Veh: n = 8,
DH376: n = 4), t-test: ∗p < 0.05, ∗∗∗p < 0.001].
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FIGURE 3 | DAGL KD does not alter 2-AG levels in Neuro-2a. (A,B) DAGL KD populations were analyzed by gel-based ABPP using probes MB064 (2 µM) and
FP-TAMRA (500 nM) (20 min, rt). Coomassie served as protein loading control. (B) Probe labeling of DAGLβ was quantified and normalized for protein loading. Data
is expressed as % of vehicle [mean ± SEM (WT: n = 9, KD: n = 3), t-test: ∗∗∗p < 0.001]. (C) Lipidomics analysis on WT and DAGL KD Neuro-2a populations treated
in situ with vehicle or DH376 (100 nM, serum-free, 2 h). Lipid abundance was normalized for the amount of protein. Data is expressed as % of vehicle [mean ± SEM
(WT: n = 8, KD: n = 4/2), t-test: ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001]. (D) DAGL KD efficiency was assessed by chemical proteomics on WT and KD Neuro-2a cells
using probes MB108 and FP-biotin (10 µM each, 30 min, 37◦C). Data is expressed as % of WT-vehicle [mean ± SEM (n = 4), t-test with Holm–Sidak multiple
comparison correction: ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001].
to introduce a reporter group via a copper(I)-catalyzed azide-
alkyne cycloaddition (“click” chemistry) (Rostovtsev et al., 2002).
Neuro-2a cells were incubated with DH376, lysed and the
covalently bound inhibitor-target complexes were conjugated to
Cy5-azide and visualized by SDS-PAGE and in-gel fluorescence
scanning (Figures 4A,B). Apart from DAGLβ, one other
fluorescent band with a molecular weight of ∼35 kDa was
detected. Competitive ABPP using MB064 and FP-TAMRA
suggested that this activity could be ABHD6, which was
previously also reported as an off-target of DH376 (Ogasawara
et al., 2016; van Rooden et al., 2018). To confirm the identity
of this protein expressed by Neuro-2a cells, chemical proteomics
was employed (Figure 4C). DAGLβ and ABHD6 were identified
as the only targets of DH376 in Neuro-2a cells (Figure 4D). Thus,
these data suggested that ABHD6 could be responsible for 2-AG
production in conjunction with DAGLβ.
α,β-Hydrolase domain containing protein 6 is known to
hydrolyze additional lipids than 2-AG, including lysophos-
phatidyl species (Thomas et al., 2013) and bis(monoacylglycero)
phosphate (Pribasnig et al., 2015). To determine if ABHD6
can use DAG as a substrate, a DAG hydrolysis assay was
developed based on fluorescent 1-nitrobenzoxadiazole-decanoyl-
2-decanoyl-sn-glycerol (NBD-DAG) substrate. Lysates from
HEK293-T cells overexpressing recombinant human ABHD6
(Figure 5A) or its catalytically inactive mutant (ABHD6S148A) as
a negative control, were incubated with NBD-DAG and analyzed
by HPTLC. Lysates from HEK293-T cells expressing DAGLα or
its catalytically inactive mutant (DAGLαS472A) served as positive
and negative controls, respectively (Supplementary Figure S3A).
Both DAGLα and ABHD6 exhibited DAG-lipase activity as
their overexpression resulted in the hydrolysis of NBD-DAG,
whereas their mutants did not (Figures 5B,C and Supplementary
Figures S3B,C), thereby showing that ABHD6 hydrolyzes the
sn-1 ester bond of an sn-1-acyl-2-decanoyl-glycerol. Of note, the
NBD-DAG hydrolysis measured in HEK293-T cells expressing
GFP reflects the conversion of the substrate by endogenous
hydrolases, including ABHD6, and to a lesser extent DAGLβ.
In view of the abundant ABHD6 activity in different brain
regions (Baggelaar et al., 2017), we tested whether ABHD6
contributes to DAG hydrolysis in mouse brain. However, no
reduction in DAG-NBD hydrolysis was observed in mouse brain
lysates treated with the selective ABHD6 inhibitor KT182 or
by comparing lysates from Abhd6−/− mouse brain and WT
controls (Supplementary Figure S4). Of note, mice could not
be age-matched which may affect expression levels. However,
aside from the loss of ABHD6 in knockout tissue, no evident
discrepancies were observed in the lipase activity profiles
(Supplementary Figure S4A).
Next, we determined if ABHD6 could also hydrolyze
endogenous DAGs in intact cells. To this end, recombinant
ABHD6 was overexpressed in HEK293-T cells (DAGLα as
positive control and the catalytically inactive mutants as
negative controls) and endogenous DAG (16:0, 20:4) levels
were determined by targeted lipidomics (Figure 5D and
Supplementary Figure S3D). Both ABHD6 and DAGLα
overexpression reduced the levels of DAG (16:0, 20:4), whereas
overexpression of the catalytically inactive mutants had no effect
on the DAG-levels. DH376 treatment of the transfected cells
prevented the reduction in DAG levels and in fact led to an
increase in this lipid species, indicating that this DAG species
serves also as an endogenous substrate for DAGLα/ABHD6.
Overexpression of ABHD6 did not affect 2-AG levels, in line
with the dual MAG/DAG-lipase character of ABHD6, whereas its
final product AA was increased (Figure 5D). In summary, these
data indicate that ABHD6 acts as a DAG/MAG-lipase using DAG
(16:0, 20:4) as an endogenous substrate.
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FIGURE 4 | DH376 targets DAGLβ and ABHD6 in Neuro-2a. Neuro-2a cells were treated in situ with vehicle or DH376 (100 nM, serum-free, 2 h) to investigate the
DH376 interaction profile. (A,B) In situ DH376 targets were visualized by gel-based ABPP after conjugation of DH376 to Cy5-azide (5 µM, 60 min, rt) or with probe
MB064 (2 µM, 20 min, rt). Coomassie served as protein loading control. (B) Probe labeling was quantified and normalized for protein loading. Data is expressed
as % of vehicle [mean ± SEM (Veh n = 9, DH376 n = 3), t-test: ∗∗∗p < 0.001]. (C) Chemical proteomics enabled DH376 target identification. Lysates of in situ
DH376 treated Neuro-2a cells were conjugated to biotin-azide (40 µM, 60 min, 37◦C). Vehicle treated samples served as a negative control. Data is expressed as
absolute abundance [mean ± SEM (n = 4), t-test: ∗∗∗p < 0.001]. (D) Competitive proteomics validated ABHD6 and DAGLβ as DH376 targets in in situ treated
Neuro-2a cells, using probes MB108 and FP-biotin (10 µM each, 30 min, 37◦C). Data is expressed as % of WT-Vehicle [mean ± SEM (n = 4), t-test with Holm–Sidak
multiple comparison correction: ∗∗∗p < 0.001].
To check whether endogenous cellular levels of 2-AG and AA
are controlled by ABHD6, a Neuro-2a ABHD6 KD population
and a triple DAGLα-β-ABHD6 KD population were generated
(Figure 6A and Supplementary Figures S2D–F). ABHD6 KD
had no effects on 2-AG or AA levels (Figure 6C), which suggests
that DAGLβ and ABHD6 activities can compensate for each
other. The KD efficiency at the protein level was reduced in the
triple DAGLα-DAGLβ-ABHD6 KD as compared to the single
KDs as determined by gel-based ABPP (Figures 6A,B) and
chemical proteomics (Figure 6D). We noticed that 40–50% of
active ABHD6 and 30–40% active DAGLβ remained. In line with
the reduced ABHD6 and DAGL activity in the triple KD, both
2-AG and AA levels were reduced by approximately 30%.
Finally, in light of the finding that ABHD6 can act as a
DAG lipase, the DAGLβ and ABHD6 activity in Neuro-2a
cells during RA-induced differentiation was mapped by gel-
based ABPP (Figure 7A). A threefold increase in the amount
of active ABHD6 was observed in differentiated Neuro-2a
cells, whereas the amount of active DAGLβ was decreased
(Figure 7B). However, inhibition of ABHD6 by the ABHD6
inhibitor KT182 did not abolish the 2-AG increase during
RA-induced differentiation (Supplementary Figure S5). As the
dual ABHD6/DAGL inhibitor DH376 inhibitor did reduce 2-AG
levels and differentiation (Figure 2), these data suggest that the
RA-induced 2-AG production (Figure 1B) in Neuro-2a cells is
due to combined DAGLβ and ABHD6 activity.
DISCUSSION
In the present study, we extend our understanding of ABHD6
to a dual DAG/MAG-lipase that produces 2-AG. We also
show that ABHD6 activity is involved in 2-AG production in
Neuro-2a cells during RA-induced differentiation. Previously, it
was shown that the RA-induced neurite outgrowth is a CB1R
dependent process (Jung et al., 2011). The dual ABDH6/DAGL
inhibitor DH376 reduced RA-induced Neuro-2a differentiation,
thereby supporting the notion that 2-AG is involved in this
process. Nevertheless, it is likely that other lipid mediators
also play a role, because DH376 did not abolish neurite
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FIGURE 5 | Recombinant ABHD6 possesses DAG-lipase activity in vitro and in situ. HEK293-T cells were transiently transfected with GFP, ABHD6 or its catalytically
inactive serine mutant (S148A) and treated in situ with vehicle or DH376 (DH, 1 µM, 2 h, serum-free). (A) Protein activity and expression was confirmed by gel-based
ABPP and western blot. Samples were subsequently incubated with probes MB064 (red; 500 nM, 10 min, rt), FP-BODIPY (green; 500 nM, 10 min, rt), and
Cy5-azide click mix (blue; 2.5 µM, 30 min, rt). Coomassie served as a protein loading control. Western blot with mouse-anti-FLAG (1:2500, 45 min, rt) verified
expression of the catalytically inactive protein. (B,C) Whole cell lysates were incubated with DAG-NBD (5 µM, 30 min, 37◦C), lipids were extracted and analyzed by
HPTLC. (C) DAG hydrolysis was quantified and expressed as % of GFP [mean ± SEM (n = 3), t-test: ∗∗∗p < 0.001]. (D) Lipid abundance of transfected and in situ
treated cells was measured and normalized to the amount of protein. Data is expressed as % of GFP-Vehicle [mean ± SEM (n = 4), t-test: ∗p < 0.05, ∗∗p < 0.01].
FIGURE 6 | Neuro-2a DAGLα–β-ABHD6 triple KD populations have decreased 2-AG levels. (A,B) ABHD6 and DAGLα–β-ABHD6 KD populations were analyzed by
gel-based ABPP using probes MB064 (2 µM) and FP-TAMRA (500 nM) (20 min, rt). Coomassie served as a protein loading control. (B) Probe labeling was
normalized for protein loading. Data is expressed as % of vehicle [mean ± SEM (WT: n = 9, KD: n = 3), t-test: ∗∗∗p < 0.001]. (C) Lipidomics analysis on WT and
ABHD6 KD Neuro-2a populations treated in situ with vehicle or DH376 (100 nM, serum-free, 2 h). Lipid abundance was normalized for the amount of protein. Data is
expressed as % of vehicle [mean ± SEM (WT: n = 8, KD: n = 4/2), t-test: ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001]. (D) DAGL and ABHD6 KD efficiency was assessed
by chemical proteomics on WT and KD Neuro-2a populations using probes MB108 and FP-biotin (10 µM each, 30 min, 37◦C). Data is expressed as % of
WT-vehicle [mean ± SEM (n = 4), t-test with Holm–Sidak multiple comparison correction: ∗∗p < 0.01, ∗∗∗p < 0.001].
outgrowth and AEA and AA levels were dramatically increased
during differentiation.
α,β-hydrolase domain containing protein 6 is a highly
conserved metabolic hydrolase that belongs to the serine
hydrolase family (Navia-Paldanius et al., 2012), mainly known
as a 2-AG hydrolytic enzyme, but its substrates also include
other monoacylglycerols (Navia-Paldanius et al., 2012), as well
as various lysophosphatidyl species (Thomas et al., 2013)
and bis(monoacylglycero)phosphate (Pribasnig et al., 2015).
Using biochemical, genetic, and pharmacological approaches,
we expanded the substrate scope of ABHD6 toward DAGs.
Considering both MAG and DAG hydrolysis are mediated by
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FIGURE 7 | Levels of active DAGLβ decreased while active ABHD6 levels increased during RA-induced differentiation of Neuro-2a. Neuro-2a cells were stimulated
by in situ treatment with retinoic acid (RA, 50 µM, 2% serum, 72 h). (A) Whole lysates of vehicle or RA stimulated cells were analyzed by gel-based ABPP using
activity-based probes MB064 (2 µM) or FP-TAMRA (500 nM) (20 min, rt). Coomassie served as a protein loading control. (B) Probe labeling was normalized to
loading control. Data is expressed as % of vehicle [mean ± SEM (n = 3), t-test, ∗∗∗p < 0.001].
the same catalytic serine (S148) (Figure 5; Navia-Paldanius
et al., 2012), the respective MAG- and DAG-activities are
therefore likely to be driven by relative substrate and product
concentrations rather than by regulatory mechanisms. Our data
indicate that 2-AG and AA are both produced by DAGL and
ABHD6 during neuronal differentiation.
Although ABHD6 accounts for only 4% of 2-AG hydrolysis
in mouse brain homogenates (Blankman et al., 2007), it
is an important factor of MAG hydrolysis in specific cell-
or tissues types, for example, in BV-2 cells where MAGL
is lacking (Muccioli et al., 2007). In a similar fashion,
the contribution of ABHD6 to DAG hydrolysis and 2-AG
biosynthesis in the whole brain is likely to be limited, but it
may be more pronounced in specific cell-types and physiological
processes in the absence of DAGLα or DAGLβ. In the
adult central nervous system, the postsynaptic localization
of ABHD6 (Marrs et al., 2010) would indeed allow for
retrograde endocannabinoid signaling. In the young brain,
ABHD6 mRNA is found detected in progenitor cells (Gokce
et al., 2016), which may provide an additional mechanism
for cell-autonomous eCB-signaling (Goncalves et al., 2008).
Notably, the localization of MAGL is complementary to that
of ABHD6 (Straiker et al., 2009) with MAGL mainly localized
at the presynaptic site. In a global MAGL KO mouse model
no compensatory effects were observed by ABHD6 (Taschler
et al., 2011). Similarly, ABHD6 deletion using antisense
oligonucleotides did not affect MAGL activity in peripheral tissue
(Thomas et al., 2013). Taken together, this suggests that, despite
both being MAGLs, the physiological functions of ABHD6 and
MAGL may be distinct.
Recent studies suggest that ABHD6 inhibitor have promising
therapeutic efficacy in several preclinical mouse models of
devastating diseases (Cao et al., 2019), such as metabolic
syndrome (Thomas et al., 2013), chronic inflammation
(Alhouayek et al., 2013), diabetes (Zhao et al., 2014),
including traumatic brain injury (Tchantchou and Zhang,
2013), multiple sclerosis (Manterola et al., 2018), and epilepsy
(Naydenov et al., 2014). Thus, it is important to further study
the impact of the DAG lipase activity of ABHD6 on these
pathophysiological processes to help develop novel therapeutics
based on inhibiting ABHD6 activity.
CONCLUSION
We discovered that ABHD6 hydrolyzes DAG, thereby contri-
buting to the production of the bioactive signaling lipid 2-
AG during RA-induced differentiation of Neuro-2a cells. Our
finding is supported by biochemical, genetic and pharmacological
evidence. First, genetic knockdown of both DAGLα and DAGLβ
in Neuro-2a cells had no effect on cellular 2-AG levels. Second,
the dual DAGL/ABHD6 inhibitor DH376 abolished cellular
2-AG levels. Third, ABHD6 catalyzed the degradation of a
fluorescent DAG substrate. Fourth, overexpression of ABHD6,
but not its catalytically inactive mutant, reduced endogenous
DAG (16:0, 20:4) levels, which was inhibited by DH376. Fifth,
cellular 2-AG levels decreased upon triple KD of DAGLα-
β-ABHD6 in Neuro-2a. These data extend the role of ABHD6
from a MAG lipase to a DAG lipase and suggest a potential role
for ABHD6 in neuronal differentiation.
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